Liver transplantation for hepatitis B

Steven Huy Bui Han, Paul Martin

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Recurrent HBV is almost universal post-LT and is accompanied by significant graft and patient loss in the absence of effective immunoprophylaxis. Hepatitis B immunoglobulin (HBIG) monotherapy and lamivudine monotherapy significantly reduce the rate of recurrent hepatitis B, but recurrent hepatitis B still occurs in up to 25% due to the emergence of resistant mutants. Combination administration of HBIG and lamivudine is more efficacious in preventing recurrent hepatitis B, decreasing recurrence rates of hepatitis B to 0-18% in studies. Future studies to determine the optimal dosing regimen and duration of HBIG and lamivudine and to evaluate the efficacy of newer antivirals such as adefovir dipivoxil in preventing recurrent HBV are needed.Treatment of established recurrent hepatitis B remains problematic. Lamivudine has shown promise during the initial treatment period, but is plagued by rapid development of viral resistance with longer treatment duration. Adefovir dipivoxil appears very promising, and further studies are needed to evaluate its efficacy in the post-liver transplant patient. Interferon-alfa's use in the post-liver transplant patient is limited given the availability of the newer antiviral drugs. Famciclovir and ganciclovir have shown some promise in treating recurrent HBV, but have been replaced by newer agents such as lamivudine and adefovir.

Original languageEnglish
Pages (from-to)193-201
Number of pages9
JournalHepatology Research
Volume29
Issue number4
DOIs
StatePublished - Aug 1 2004
Externally publishedYes

Fingerprint

Hepatitis B
Liver Transplantation
Lamivudine
Immunoglobulins
Transplants
Antiviral Agents
Ganciclovir
Liver
Interferon-alpha
Therapeutics
Recurrence

Keywords

  • Adefovir dipivoxil
  • HBIG
  • Lamivudine
  • Liver transplantation
  • Prophylaxis
  • Recurrent hepatitis B

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Liver transplantation for hepatitis B. / Bui Han, Steven Huy; Martin, Paul.

In: Hepatology Research, Vol. 29, No. 4, 01.08.2004, p. 193-201.

Research output: Contribution to journalArticle

Bui Han, Steven Huy ; Martin, Paul. / Liver transplantation for hepatitis B. In: Hepatology Research. 2004 ; Vol. 29, No. 4. pp. 193-201.
@article{7a53d991588a4b26ac78aad0fd044a85,
title = "Liver transplantation for hepatitis B",
abstract = "Recurrent HBV is almost universal post-LT and is accompanied by significant graft and patient loss in the absence of effective immunoprophylaxis. Hepatitis B immunoglobulin (HBIG) monotherapy and lamivudine monotherapy significantly reduce the rate of recurrent hepatitis B, but recurrent hepatitis B still occurs in up to 25{\%} due to the emergence of resistant mutants. Combination administration of HBIG and lamivudine is more efficacious in preventing recurrent hepatitis B, decreasing recurrence rates of hepatitis B to 0-18{\%} in studies. Future studies to determine the optimal dosing regimen and duration of HBIG and lamivudine and to evaluate the efficacy of newer antivirals such as adefovir dipivoxil in preventing recurrent HBV are needed.Treatment of established recurrent hepatitis B remains problematic. Lamivudine has shown promise during the initial treatment period, but is plagued by rapid development of viral resistance with longer treatment duration. Adefovir dipivoxil appears very promising, and further studies are needed to evaluate its efficacy in the post-liver transplant patient. Interferon-alfa's use in the post-liver transplant patient is limited given the availability of the newer antiviral drugs. Famciclovir and ganciclovir have shown some promise in treating recurrent HBV, but have been replaced by newer agents such as lamivudine and adefovir.",
keywords = "Adefovir dipivoxil, HBIG, Lamivudine, Liver transplantation, Prophylaxis, Recurrent hepatitis B",
author = "{Bui Han}, {Steven Huy} and Paul Martin",
year = "2004",
month = "8",
day = "1",
doi = "10.1016/j.hepres.2004.02.015",
language = "English",
volume = "29",
pages = "193--201",
journal = "Hepatology Research",
issn = "1386-6346",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Liver transplantation for hepatitis B

AU - Bui Han, Steven Huy

AU - Martin, Paul

PY - 2004/8/1

Y1 - 2004/8/1

N2 - Recurrent HBV is almost universal post-LT and is accompanied by significant graft and patient loss in the absence of effective immunoprophylaxis. Hepatitis B immunoglobulin (HBIG) monotherapy and lamivudine monotherapy significantly reduce the rate of recurrent hepatitis B, but recurrent hepatitis B still occurs in up to 25% due to the emergence of resistant mutants. Combination administration of HBIG and lamivudine is more efficacious in preventing recurrent hepatitis B, decreasing recurrence rates of hepatitis B to 0-18% in studies. Future studies to determine the optimal dosing regimen and duration of HBIG and lamivudine and to evaluate the efficacy of newer antivirals such as adefovir dipivoxil in preventing recurrent HBV are needed.Treatment of established recurrent hepatitis B remains problematic. Lamivudine has shown promise during the initial treatment period, but is plagued by rapid development of viral resistance with longer treatment duration. Adefovir dipivoxil appears very promising, and further studies are needed to evaluate its efficacy in the post-liver transplant patient. Interferon-alfa's use in the post-liver transplant patient is limited given the availability of the newer antiviral drugs. Famciclovir and ganciclovir have shown some promise in treating recurrent HBV, but have been replaced by newer agents such as lamivudine and adefovir.

AB - Recurrent HBV is almost universal post-LT and is accompanied by significant graft and patient loss in the absence of effective immunoprophylaxis. Hepatitis B immunoglobulin (HBIG) monotherapy and lamivudine monotherapy significantly reduce the rate of recurrent hepatitis B, but recurrent hepatitis B still occurs in up to 25% due to the emergence of resistant mutants. Combination administration of HBIG and lamivudine is more efficacious in preventing recurrent hepatitis B, decreasing recurrence rates of hepatitis B to 0-18% in studies. Future studies to determine the optimal dosing regimen and duration of HBIG and lamivudine and to evaluate the efficacy of newer antivirals such as adefovir dipivoxil in preventing recurrent HBV are needed.Treatment of established recurrent hepatitis B remains problematic. Lamivudine has shown promise during the initial treatment period, but is plagued by rapid development of viral resistance with longer treatment duration. Adefovir dipivoxil appears very promising, and further studies are needed to evaluate its efficacy in the post-liver transplant patient. Interferon-alfa's use in the post-liver transplant patient is limited given the availability of the newer antiviral drugs. Famciclovir and ganciclovir have shown some promise in treating recurrent HBV, but have been replaced by newer agents such as lamivudine and adefovir.

KW - Adefovir dipivoxil

KW - HBIG

KW - Lamivudine

KW - Liver transplantation

KW - Prophylaxis

KW - Recurrent hepatitis B

UR - http://www.scopus.com/inward/record.url?scp=4043172848&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4043172848&partnerID=8YFLogxK

U2 - 10.1016/j.hepres.2004.02.015

DO - 10.1016/j.hepres.2004.02.015

M3 - Article

VL - 29

SP - 193

EP - 201

JO - Hepatology Research

JF - Hepatology Research

SN - 1386-6346

IS - 4

ER -